Your browser doesn't support javascript.
loading
Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease.
Aschenbrenner, Andrew J; Baksh, R Asaad; Benejam, Bessy; Beresford-Webb, Jessica A; Coppus, Antonia; Fortea, Juan; Handen, Benjamin L; Hartley, Sigan; Head, Elizabeth; Jaeger, Judith; Levin, Johannes; Loosli, Sandra V; Rebillat, Anne-Sophie; Sacco, Silvia; Schmitt, Frederick A; Thurlow, Kate E; Zaman, Shahid; Hassenstab, Jason; Strydom, Andre.
Affiliation
  • Aschenbrenner AJ; Washington University in St. Louis, Department of Neurology St. Louis Missouri USA.
  • Baksh RA; Institute of Psychiatry, Psychology, and Neuroscience Department of Forensic and Neurodevelopmental Sciences King's College London London UK.
  • Benejam B; The London Down Syndrome (LonDownS) Consortium London UK.
  • Beresford-Webb JA; Barcelona Down Medical Center Fundació Catalana Síndrome de Down Barcelona Spain.
  • Coppus A; Cambridge Intellectual and Developmental Disabilities Research Group Department of Psychiatry University of Cambridge Cambridge UK.
  • Fortea J; Department of Primary and Community Care Radboud University Medical Center Nijmegen The Netherlands.
  • Handen BL; Barcelona Down Medical Center Fundació Catalana Síndrome de Down Barcelona Spain.
  • Hartley S; Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau) Neurology Department Hospital de la Santa Creu i Sant Pau Barcelona Spain.
  • Head E; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED) Madrid Spain.
  • Jaeger J; Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
  • Levin J; Department of Human Development & Family Studies University of Wisconsin-Madison Madison Wisconsin USA.
  • Loosli SV; Department of Pathology & Laboratory Medicine University of California Irvine California USA.
  • Rebillat AS; CognitionMetrics LLC. Wilmington Delaware USA.
  • Sacco S; Deptment of Psychiatry and Behavioral Sciences Albert Einstein College of Medicine Bronx New York USA.
  • Schmitt FA; Department of Neurology Ludwig-Maximilians-Universität München Munich Germany.
  • Thurlow KE; German Center for Neurodegenerative Diseases Munich Germany.
  • Zaman S; Munich Cluster for Systems Neurology (SyNergy) Munich Germany.
  • Hassenstab J; Department of Neurology Ludwig-Maximilians-Universität München Munich Germany.
  • Strydom A; Jerome Lejeune Institute Paris France.
Alzheimers Dement (Amst) ; 13(1): e12184, 2021.
Article in En | MEDLINE | ID: mdl-33969175
ABSTRACT

INTRODUCTION:

Down syndrome (DS), a genetic variant of early onset Alzheimer's disease (AD), lacks a suitable outcome measure for prevention trials targeting pre-dementia stages.

METHODS:

We used cognitive test data collected in several longitudinal aging studies internationally from 312 participants with DS without dementia to identify composites that were sensitive to change over time. We then conducted additional analyses to provide support for the utility of the composites. The composites were presented to an expert panel to determine the most optimal cognitive battery based on predetermined criteria.

RESULTS:

There were common cognitive domains across site composites, which were sensitive to early decline. The final composite consisted of memory, language/executive functioning, selective attention, orientation, and praxis tests.

DISCUSSION:

We have identified a composite that is sensitive to early decline and thus may have utility as an outcome measure in trials to prevent or delay symptoms of AD in DS.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Alzheimers Dement (Amst) Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Alzheimers Dement (Amst) Year: 2021 Document type: Article